Angiotensin II in Vasodilatory Shock

被引：10
作者：
Wakefield, Brett J. [1 ,2 ]
Busse, Laurence W. [3 ]
Khanna, Ashish K. [1 ,4 ,5 ]
机构：
[1] Cleveland Clin, Dept Gen Anesthesiol, Anesthesiol Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA
[2] Washington Univ, Div Crit Care Med, Dept Anesthesiol, Sch Med, 660 South Euclid Ave,Campus Box 8054, St Louis, MO 63110 USA
[3] Emory Univ, Emory St Josephs Hosp, Div Pulm Crit Care Allergy & Sleep Med, Sch Med, 5665 Peachtree Dunwoody Rd, Atlanta, GA 30342 USA
[4] Cleveland Clin, Dept Outcomes Res, Ctr Crit Care, 9500 Euclid Ave,G58, Cleveland, OH 44195 USA
[5] Wake Forest Univ, Bowman Gray Sch Med, Dept Anesthesiol, Winston Salem, NC 27109 USA
来源：
CRITICAL CARE CLINICS | 2019年 / 35卷 / 02期
关键词：
Vasodilatory shock; Septic shock; Angiotensin II; Vasopressor; Blood pressure; MEAN ARTERIAL-PRESSURE; SEPTIC SHOCK; ARGININE-VASOPRESSIN; CLINICAL-EXPERIENCE; ALDOSTERONE SYSTEM; CONVERTING-ENZYME; RENIN; NOREPINEPHRINE; MANAGEMENT; RECEPTORS;
D O I：
10.1016/j.ccc.2018.11.003
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
The Angiotensin II for the Treatment of Vasodilatory Shock (ATHOS-3) trial demonstrated the vasopressor effects and catecholamine-sparing properties of angiotensin II. As a result, the Food and Drug Administration has approved angiotensin II for the treatment of vasodilatory shock. This review details the goals of treatment of vasodilatory shock in addition to the history, current use, and recent research regarding the use of angiotensin II. An illustrative case of the use of angiotensin II is also incorporated for understanding the clinical utility of the drug.
引用
收藏
页码：229 / +
页数：18
相关论文
共 50 条
  • [21] Angiotensin II in septic shock
    Jadhav, Amar P.
    Sadaka, Farid G.
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2019, 37 (06) : 1169 - 1174
  • [22] Pharmacologic Agents for the Treatment of Vasodilatory Shock
    Knotzer, Hans
    Poidinger, Bernhard
    Kleinsasser, Axel
    CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (19) : 2133 - 2139
  • [23] Vasopressor Choice and Timing in Vasodilatory Shock
    Wieruszewski, Patrick M.
    Khanna, Ashish K.
    CRITICAL CARE, 2022, 26 (01)
  • [24] Advances in Vasodilatory Shock: A Concise Review
    Lahiry, Sandeep
    Thakur, Sayanta
    Chakraborty, Dwaipayan S.
    INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2019, 23 (10) : 475 - 480
  • [25] Angiotensin II: A New Vasopressor for the Treatment of Distributive Shock
    Allen, John M.
    Gilbert, Brian W.
    CLINICAL THERAPEUTICS, 2019, 41 (12) : 2594 - 2610
  • [26] Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial
    Kealy R. Ham
    David W. Boldt
    Michael T. McCurdy
    Laurence W. Busse
    Raphael Favory
    Michelle N. Gong
    Ashish K. Khanna
    Stefan N. Chock
    Feng Zeng
    Lakhmir S. Chawla
    George F. Tidmarsh
    Marlies Ostermann
    Annals of Intensive Care, 9
  • [27] Hydrocortisone in Vasodilatory Shock
    Venkatesh, Balasubramanian
    Cohen, Jeremy
    CRITICAL CARE CLINICS, 2019, 35 (02) : 263 - +
  • [28] Vasopressin in Vasodilatory Shock
    Ukor, Ida-Fong
    Walley, Keith R.
    CRITICAL CARE CLINICS, 2019, 35 (02) : 247 - +
  • [29] The use of angiotensin II in distributive shock
    Chawla, Lakhmir S.
    Busse, Laurence W.
    Brasha-Mitchell, Ermira
    Alotaibi, Ziyad
    CRITICAL CARE, 2016, 20
  • [30] Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock
    Daniel E. Leisman
    Damian R. Handisides
    Lakhmir S. Chawla
    Timothy E. Albertson
    Laurence W. Busse
    David W. Boldt
    Adam M. Deane
    Michelle N. Gong
    Kealy R. Ham
    Ashish K. Khanna
    Marlies Ostermann
    Michael T. McCurdy
    B. Taylor Thompson
    James S. Tumlin
    Christopher D. Adams
    Tony N. Hodges
    Rinaldo Bellomo
    Annals of Intensive Care, 13
12345